UNLABELLED: Glycerol phenylbutyrate is under development for treatment of urea cycle disorders (UCDs), rare inherited metabolic disorders manifested by hyperammonemia and neurological impairment. We report the results of a pivotal Phase 3, randomized, double-blind, crossover trial comparing ammonia control, assessed as 24-hour area under the curve (NH3 -AUC0-24hr ), and pharmacokinetics during treatment with glycerol phenylbutyrate versus sodium phenylbutyrate (NaPBA) in adult UCD patients and the combined results of four studies involving short- and long-term glycerol phenylbutyrate treatment of UCD patients ages 6 and above. Glycerol phenylbutyrate was noninferior to NaPBA with respect to ammonia control in the pivotal study, with mean (standard deviation, SD) NH3 -AUC0-24hr of 866 (661) versus 977 (865) μmol·h/L for glycerol phenylbutyrate and NaPBA, respectively. Among 65 adult and pediatric patients completing three similarly designed short-term comparisons of glycerol phenylbutyrate versus NaPBA, NH3 -AUC0-24hr was directionally lower on glycerol phenylbutyrate in each study, similar among all subgroups, and significantly lower (P < 0.05) in the pooled analysis, as was plasma glutamine. The 24-hour ammonia profiles were consistent with the slow-release behavior of glycerol phenylbutyrate and better overnight ammonia control. During 12 months of open-label glycerol phenylbutyrate treatment, average ammonia was normal in adult and pediatric patients and executive function among pediatric patients, including behavioral regulation, goal setting, planning, and self-monitoring, was significantly improved. CONCLUSION:Glycerol phenylbutyrate exhibits favorable pharmacokinetics and ammonia control relative to NaPBA in UCD patients, and long-term glycerol phenylbutyrate treatment in pediatric UCD patients was associated with improved executive function (ClinicalTrials.gov NCT00551200, NCT00947544, NCT00992459, NCT00947297). (HEPATOLOGY 2012).
RCT Entities:
UNLABELLED: Glycerol phenylbutyrate is under development for treatment of urea cycle disorders (UCDs), rare inherited metabolic disorders manifested by hyperammonemia and neurological impairment. We report the results of a pivotal Phase 3, randomized, double-blind, crossover trial comparing ammonia control, assessed as 24-hour area under the curve (NH3 -AUC0-24hr ), and pharmacokinetics during treatment with glycerol phenylbutyrate versus sodium phenylbutyrate (NaPBA) in adult UCD patients and the combined results of four studies involving short- and long-term glycerol phenylbutyrate treatment of UCD patients ages 6 and above. Glycerol phenylbutyrate was noninferior to NaPBA with respect to ammonia control in the pivotal study, with mean (standard deviation, SD) NH3 -AUC0-24hr of 866 (661) versus 977 (865) μmol·h/L for glycerol phenylbutyrate and NaPBA, respectively. Among 65 adult and pediatric patients completing three similarly designed short-term comparisons of glycerol phenylbutyrate versus NaPBA, NH3 -AUC0-24hr was directionally lower on glycerol phenylbutyrate in each study, similar among all subgroups, and significantly lower (P < 0.05) in the pooled analysis, as was plasma glutamine. The 24-hour ammonia profiles were consistent with the slow-release behavior of glycerol phenylbutyrate and better overnight ammonia control. During 12 months of open-label glycerol phenylbutyrate treatment, average ammonia was normal in adult and pediatric patients and executive function among pediatric patients, including behavioral regulation, goal setting, planning, and self-monitoring, was significantly improved. CONCLUSION:Glycerol phenylbutyrate exhibits favorable pharmacokinetics and ammonia control relative to NaPBA in UCD patients, and long-term glycerol phenylbutyrate treatment in pediatric UCD patients was associated with improved executive function (ClinicalTrials.gov NCT00551200, NCT00947544, NCT00992459, NCT00947297). (HEPATOLOGY 2012).
Authors: Roger F Butterworth; Michael D Norenberg; Vicente Felipo; Peter Ferenci; Jan Albrecht; Andres T Blei Journal: Liver Int Date: 2009-07 Impact factor: 5.828
Authors: A L Gropman; S T Fricke; R R Seltzer; A Hailu; A Adeyemo; A Sawyer; J van Meter; W D Gaillard; R McCarter; M Tuchman; M Batshaw Journal: Mol Genet Metab Date: 2008-07-26 Impact factor: 4.797
Authors: Mendel Tuchman; Brendan Lee; Uta Lichter-Konecki; Marshall L Summar; Marc Yudkoff; Stephen D Cederbaum; Douglas S Kerr; George A Diaz; Margaretta R Seashore; Hye-Seung Lee; Robert J McCarter; Jeffrey P Krischer; Mark L Batshaw Journal: Mol Genet Metab Date: 2008-06-17 Impact factor: 4.797
Authors: Lauren Krivitzky; Talin Babikian; Hye-Seung Lee; Nina Hattiangadi Thomas; Karen L Burk-Paull; Mark L Batshaw Journal: Pediatr Res Date: 2009-07 Impact factor: 3.756
Authors: Gregory M Enns; Susan A Berry; Gerard T Berry; William J Rhead; Saul W Brusilow; Ada Hamosh Journal: N Engl J Med Date: 2007-05-31 Impact factor: 91.245
Authors: Nina Hediger; Markus A Landolt; Carmen Diez-Fernandez; Martina Huemer; Johannes Häberle Journal: J Inherit Metab Dis Date: 2018-03-08 Impact factor: 4.982
Authors: Roland Posset; Andrea L Gropman; Sandesh C S Nagamani; Lindsay C Burrage; Jirair K Bedoyan; Derek Wong; Gerard T Berry; Matthias R Baumgartner; Marc Yudkoff; Matthias Zielonka; Georg F Hoffmann; Peter Burgard; Andreas Schulze; Shawn E McCandless; Angeles Garcia-Cazorla; Jennifer Seminara; Sven F Garbade; Stefan Kölker Journal: Ann Neurol Date: 2019-05-13 Impact factor: 10.422
Authors: M Mokhtarani; G A Diaz; W Rhead; S A Berry; U Lichter-Konecki; A Feigenbaum; A Schulze; N Longo; J Bartley; W Berquist; R Gallagher; W Smith; S E McCandless; C Harding; D C Rockey; J M Vierling; P Mantry; M Ghabril; R S Brown; K Dickinson; T Moors; C Norris; D Coakley; D A Milikien; S C Nagamani; C Lemons; B Lee; B F Scharschmidt Journal: Mol Genet Metab Date: 2013-10-08 Impact factor: 4.797
Authors: Susan A Berry; Uta Lichter-Konecki; George A Diaz; Shawn E McCandless; William Rhead; Wendy Smith; Cynthia Lemons; Sandesh C S Nagamani; Dion F Coakley; Masoud Mokhtarani; Bruce F Scharschmidt; Brendan Lee Journal: Mol Genet Metab Date: 2014-02-21 Impact factor: 4.797
Authors: Sandesh C S Nagamani; George A Diaz; William Rhead; Susan A Berry; Cynthia Le Mons; Uta Lichter-Konecki; James Bartley; Annette Feigenbaum; Andreas Schulze; Nicola Longo; William Berquist; Renata Gallagher; Dennis Bartholomew; Cary O Harding; Mark S Korson; Shawn E McCandless; Wendy Smith; Jerry Vockley; David Kronn; Robert Zori; Stephen Cederbaum; J Lawrence Merritt; Derek Wong; Dion F Coakley; Bruce F Scharschmidt; Klara Dickinson; Miguel Marino; Brendan H Lee; Masoud Mokhtarani Journal: Mol Genet Metab Date: 2015-08-05 Impact factor: 4.797
Authors: B Lee; G A Diaz; W Rhead; U Lichter-Konecki; A Feigenbaum; S A Berry; C Le Mons; J Bartley; N Longo; S C Nagamani; W Berquist; R C Gallagher; C O Harding; S E McCandless; W Smith; A Schulze; M Marino; R Rowell; D F Coakley; M Mokhtarani; B F Scharschmidt Journal: Mol Genet Metab Date: 2015-11-11 Impact factor: 4.797